D. E. Shaw & Co., Inc. Uro Gen Pharma Ltd. Transaction History
D. E. Shaw & Co., Inc.
- $125 Billion
- Q2 2025
A detailed history of D. E. Shaw & Co., Inc. transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 27,432 shares of URGN stock, worth $494,873. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27,432Holding current value
$494,873% of portfolio
0.0%Shares
4 transactions
Others Institutions Holding URGN
# of Institutions
163Shares Held
39.6MCall Options Held
2.06MPut Options Held
717K-
Rtw Investments, LP New York, NY4.54MShares$82 Million0.96% of portfolio
-
Toronto Dominion Bank Toronto, Ontario, A63.19MShares$57.6 Million0.08% of portfolio
-
Morgan Stanley New York, NY2.48MShares$44.7 Million0.0% of portfolio
-
Jefferies Financial Group Inc. New York, NY2.2MShares$39.7 Million0.27% of portfolio
-
Black Rock Inc. New York, NY2.19MShares$39.6 Million0.0% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $410M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...